Gulf Regional Recommendations

*HD recommended to be used over SD in specific at-risk groups in most of the regions.
HD: high-dose; SD: standard-dose.
Cut off date: May 2026

Gulf Countries Health Authorities preferentially recommend influenza high-dose vaccine for the Older adults

In addition to scientific societies, independent expert groups advocate for the adoption of the HD vaccine to enhance protection for older adults- example

MENA-ISN and researchers from GCC countries have published an article advocating the implementation of HD seasonal influenza vaccine in these countries to improve the protection of individuals aged 65 years and older

The Saudi Heart Association (SHA) has published a landmark Position Statement on Adult Vaccinations for Cardiovascular Disease Patients – a testament to the power of HD evidence.

Influenza vaccination has been consistently associated with a reduction in mortality and hospitalizations" and highlights a 28% reduction in MACE and 41% reduction in cardiovascular mortality when vaccination is administered within three days of hospitalization for myocardial infarction

"For patients aged 60 and above, particularly those at increased risk such as individuals with cardiovascular conditions, the high-dose influenza vaccine is preferred as it offers superior immunogenicity and effectiveness compared to the standard dose. Lowering the eligibility age for high-dose vaccination to 60 years ensures enhanced protection in this vulnerable group. "

"In the context of Saudi Arabia, it is particularly important to advise patients to consult their healthcare provider prior to Hajj or Umrah in order to assess their medical fitness and reduce the risk of infection during these mass gatherings. SHA stated influenza, COVID-19, and meningococcal (quadrivalent ACWY) vaccination is mandatory for Hajj.

The Emirates Diabetes and Endocrine Society (EDES) has released its updated Type 2 Diabetes guideline, now recommending High-Dose influenza vaccination for older adults — recognizing this population's heightened vulnerability to influenza-related complications. This milestone reinforces the growing scientific consensus on tailored protection for those who need it most. Explore the full guideline recommendations here: